Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16104507 | 1.00 | TDP1 (0.35) | TDP1OPRK1OPRM1HTR1AALDH1A1 | |
| SCHEMBL14997653 | 0.90 | TDP1 (0.35) | TDP1OPRK1OPRM1HTR1AALDH1A1 | |
| SCHEMBL16104526 | 0.90 | TDP1 (0.35) | TDP1OPRK1OPRM1HTR1AALDH1A1 | |
| SCHEMBL16498720 | 0.78 | TDP1 (0.36) | TDP1OPRK1OPRM1HTR1AALDH1A1 | |
| SCHEMBL19522797 | 0.76 | ALDH1A1 (0.36) | TDP1OPRK1OPRM1HTR1AALDH1A1 | |
| SCHEMBL21595432 | 0.70 | PRSS1 (0.50) | TDP1OPRK1OPRM1HTR1AALDH1A1 | |
| SCHEMBL16499472 | 0.67 | — | — | |
| SCHEMBL10779350 | 0.66 | BRD4 (0.39) | TDP1OPRK1OPRM1HTR1ACHRM5 | |
| SCHEMBL11834734 | 0.64 | F2R (0.39) | — | |
| SCHEMBL29348295 | 0.63 | HTR1A (0.30) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993470-B2 | Catalysts for the alkyne metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-8993470-B2 | Catalysts for the alkyne metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | MSH6, AP3M1, PMS2 | TDP1 3065/4885OPRK1 1973/4885OPRM1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.